|AHFS/Drugs.com||International Drug Names|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||385.376 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Pathohistochemical studies have revealed that the volume of the infarction in the middle cerebral artery occlusion model could be decreased by nilvadipine.
This section may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. (December 2017) (Learn how and when to remove this template message)
Nilvadipine was tested in clinical trial as a possible treatment for Alzheimer's disease in Ireland by the Roskamp Institute, Florida, USA and Trinity College, Ireland. Following this study, an international research consortium led by Trinity College Dublin (Ireland) in May 2011 announced the selection for funding of a large-scale European clinical trial of nilvadipine. More than 500 Alzheimer's disease patients will participate in the multicenter phase III clinical trial designed to study the effectiveness of nilvadipine.[needs update]
- "Roskamp Nilvadipine Clinical Trial Questions and Answers" (Press release). Roskamp Institute.
- "Roskamp Nilvadipine Clinical Trial Press Release" (Press release). Roskamp Institute.
|This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.|